Drug
Tsra 196
Tsra 196: highest development phase Phase 1/2, developed by Tessera Therapeutics, Inc.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Tessera Therapeutics, Inc.
Trials
| Drug | Phase | Indication |
|---|---|---|
| TSRA-196 NCT07227207 | Phase 1/2 | Alpha-1 Antitrypsin Deficiency (AATD) |
Latest
No recent events.
Follow Tsra 196 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.